Table 5.6f

Immunosuppression Use for Maintenance by Regimen

One Year Following Transplantation, 1995 to 2004

Recipients with Kidney Transplants

  Transplant Year
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004
Transplants 11,081 11,397 11,701 12,451 12,758 13,611 14,265 14,778 15,136 16,004
Functioning Graft at 1 Year PostTx 9,463 9,905 10,233 10,825 11,043 11,831 12,723 13,254 13,572 14,302
With Maintenance Use Recorded at 1 Year PostTx 636 808 1,537 6,744 10,468 11,216 12,493 12,935 13,222 13,958
--- + MMF/MPA 5.7% 1.5% 1.7% 0.3% 0.1% 0.0% 0.1% 0.1% 0.1% 0.2%
--- + MMF/MPA + Other Antimet 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
--- + MMF/MPA + Siro/Evero 0.0% 0.0% 0.0% 0.0% 0.0% 0.1% 0.3% 0.5% 1.1% 1.3%
--- + MMF/MPA + Steroids 0.6% 0.9% 0.8% 1.2% 1.5% 0.9% 0.9% 0.9% 0.8% 0.8%
--- + Other Antimet 0.0% 0.1% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
--- + Other Antimet + Siro/Evero 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
--- + Other Antimet + Steroids 0.5% 0.6% 0.1% 0.2% 0.2% 0.1% 0.1% 0.1% 0.1% 0.0%
--- + Siro/Evero 0.8% 0.0% 0.3% 0.1% 0.1% 0.2% 0.2% 0.1% 0.1% 0.2%
--- + Siro/Evero + Steroids 0.0% 0.0% 0.0% 0.2% 0.3% 0.5% 0.7% 0.7% 0.6% 0.7%
--- + Steroids 0.5% 3.3% 2.3% 0.7% 0.5% 0.6% 0.7% 0.5% 0.4% 0.3%
CyA 0.5% 0.1% 0.3% 0.3% 0.7% 0.6% 0.1% 0.1% 0.1% 0.1%
CyA + MMF/MPA 0.6% 1.2% 0.9% 0.9% 0.5% 1.0% 1.1% 1.5% 1.9% 2.0%
CyA + MMF/MPA + Siro/Evero 0.0% 0.0% 0.0% 0.0% 0.0% 0.2% 0.0% 0.1% 0.1% 0.0%
CyA + MMF/MPA + Steroids 16.7% 33.7% 37.0% 41.4% 39.2% 31.7% 24.2% 19.9% 15.5% 12.6%
CyA + Other Antimet 0.5% 0.4% 0.0% 0.3% 0.2% 0.1% 0.0% 0.0% 0.0% 0.0%
CyA + Other Antimet + Siro/Evero 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
CyA + Other Antimet + Steroids 30.7% 11.4% 5.8% 5.6% 5.4% 3.0% 1.7% 0.9% 0.5% 0.4%
CyA + Siro/Evero 0.2% 0.1% 0.0% 0.0% 0.2% 0.3% 0.2% 0.7% 1.0% 0.9%
CyA + Siro/Evero + Steroids 0.0% 0.9% 1.5% 2.5% 2.1% 4.0% 3.3% 2.7% 2.0% 1.5%
CyA + Steroids 11.9% 11.5% 10.5% 7.8% 6.6% 4.3% 2.5% 1.6% 1.5% 1.2%
Tac 0.5% 0.6% 0.8% 0.5% 0.5% 0.5% 1.1% 1.8% 2.1% 2.2%
Tac + MMF/MPA 0.2% 1.2% 2.3% 1.4% 1.7% 1.8% 2.8% 5.7% 8.2% 14.1%
Tac + MMF/MPA + Siro/Evero 0.0% 0.0% 0.0% 0.0% 0.0% 0.3% 0.3% 0.4% 0.8% 0.7%
Tac + MMF/MPA + Steroids 4.9% 12.5% 17.6% 24.5% 28.3% 31.5% 37.5% 39.8% 42.6% 42.9%
Tac + Other Antimet 0.0% 0.1% 0.0% 0.1% 0.1% 0.2% 0.1% 0.1% 0.1% 0.2%
Tac + Other Antimet + Siro/Evero 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Tac + Other Antimet + Steroids 2.5% 2.5% 2.5% 2.6% 2.2% 1.9% 2.0% 1.5% 1.3% 1.0%
Tac + Siro/Evero 0.0% 0.0% 0.0% 0.0% 0.1% 0.7% 1.5% 2.2% 2.4% 2.1%
Tac + Siro/Evero + Steroids 0.0% 0.0% 0.0% 0.1% 1.0% 4.7% 7.1% 5.9% 5.1% 3.5%
Tac + Steroids 5.3% 7.2% 6.2% 6.3% 5.9% 6.3% 5.8% 5.7% 4.8% 3.9%
Other Regimen 17.6% 10.1% 9.4% 2.8% 2.8% 4.4% 5.5% 6.4% 6.5% 7.2%


Source: OPTN/SRTR Data as of May 1, 2006.

Percentages are calculated based on the total number of patients with maintenance use at one year following transplantation. They sum to 100 percent for each column.

---: No Calcineurin Inhibitor Use; CyA: Cyclosporine; Tac: Tacrolimus.

MMF: Mycophenolate Mofetil; MPA: Mycophenolate Sodium; Siro: Sirolimus; Evero: Everolimus; Other Antimet: Antimetabolites excluding MMF and MPA.

"Other Regimen" includes drug combinations that are different from the listed regimens and drugs from the text field entering.